DelveInsight’s “Exocrine Pancreatic Insufficiency Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Exocrine Pancreatic Insufficiency, historical and forecasted epidemiology as well as the Exocrine Pancreatic Insufficiency market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Exocrine Pancreatic Insufficiency market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Exocrine Pancreatic Insufficiency Market Forecast

Some of the key facts of the Exocrine Pancreatic Insufficiency Market Report: 

• The Exocrine Pancreatic Insufficiency market size was valued approximately USD 2,500 million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In April 2022, Alcresta Therapeutics, Inc., a prominent commercial-stage company dedicated to the development and commercialization of innovative enzyme-based products, revealed a set of significant milestones for RELiZORB.
• In February 2022, Researchers from the University of Miami conducted a survey with patients regarding their utilization of pancreatic enzyme replacement therapy (PERT) and identified a deficiency in education about this treatment.
• Within the 7MM, the United States recorded the highest prevalence of EPI, with a total of 176,112 cases in 2021, and projections indicate a further increase during the forecast period (2022–2032).
• According to Delveinsight’s analysis in Germany, there were a combined total of 10,088, 24,665, 5,792, and 4,704 cases of EPI resulting from Acute Pancreatitis, Chronic Pancreatitis, Cystic Fibrosis, and Unresectable Pancreatic Cancer, respectively, in the year 2021.
• Key Exocrine Pancreatic Insufficiency Companies: First Wave BioPharma, Abbott Products, AAIPharma, Solvay Pharmaceuticals, Abbott, Forest Laboratories, First Wave BioPharma, Inc., Anthera Pharmaceuticals, and others
• Key Exocrine Pancreatic Insufficiency Therapies: FWEPI/MS1819, Pancreatin, VIOKASE 16, Pancrelipase Delayed Release, SA-001, EUR-1008, adrulipase, Liprotamase, and others
• The Exocrine Pancreatic Insufficiency epidemiology based on gender analyzed that No gender difference was observed in the case of EPI
• The Exocrine Pancreatic Insufficiency market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Exocrine Pancreatic Insufficiency pipeline products will significantly revolutionize the Exocrine Pancreatic Insufficiency market dynamics.

Exocrine Pancreatic Insufficiency Overview

Exocrine Pancreatic Insufficiency (EPI) is a condition where the pancreas is unable to produce and release enough digestive enzymes into the small intestine to properly break down and absorb nutrients from food. These digestive enzymes, including lipase, protease, and amylase, play a crucial role in the digestion of fats, proteins, and carbohydrates.

Get a Free sample for the Exocrine Pancreatic Insufficiency Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market

Exocrine Pancreatic Insufficiency Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Exocrine Pancreatic Insufficiency Epidemiology Segmentation:

The Exocrine Pancreatic Insufficiency market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Exocrine Pancreatic Insufficiency
• Prevalent Cases of Exocrine Pancreatic Insufficiency by severity
• Gender-specific Prevalence of Exocrine Pancreatic Insufficiency
• Diagnosed Cases of Episodic and Chronic Exocrine Pancreatic Insufficiency

Download the report to understand which factors are driving Exocrine Pancreatic Insufficiency epidemiology trends @ Exocrine Pancreatic Insufficiency Epidemiology Forecast

Exocrine Pancreatic Insufficiency Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Exocrine Pancreatic Insufficiency market or expected to get launched during the study period. The analysis covers Exocrine Pancreatic Insufficiency market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Exocrine Pancreatic Insufficiency Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Exocrine Pancreatic Insufficiency Therapies and Key Companies

• FWEPI/MS1819: First Wave BioPharma
• Pancreatin: Abbott Products
• VIOKASE 16: AAIPharma
• Pancrelipase Delayed Release: Solvay Pharmaceuticals
• SA-001: Abbott
• EUR-1008: Forest Laboratories
• adrulipase: First Wave BioPharma, Inc.
• Liprotamase: Anthera Pharmaceuticals

Discover more about therapies set to grab major Exocrine Pancreatic Insufficiency market share @ Exocrine Pancreatic Insufficiency Treatment Landscape

Exocrine Pancreatic Insufficiency Market Drivers

• Delivery system strategies
• Advanced therapeutics for the treatment of exocrine pancreatic insufficiency
• Increasing global occurrence of exocrine pancreatic insufficiency
• Research and developmental strategies

Exocrine Pancreatic Insufficiency Market Barriers

• Lack of technological reach and awareness
• Lack of confidence in diagnosis and management
• Treatment failure to stimulate and follow society’s goals and requirements

Scope of the Exocrine Pancreatic Insufficiency Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Exocrine Pancreatic Insufficiency Companies: First Wave BioPharma, Abbott Products, AAIPharma, Solvay Pharmaceuticals, Abbott, Forest Laboratories, First Wave BioPharma, Inc., Anthera Pharmaceuticals, and others
• Key Exocrine Pancreatic Insufficiency Therapies: FWEPI/MS1819, Pancreatin, VIOKASE 16, Pancrelipase Delayed Release, SA-001, EUR-1008, adrulipase, Liprotamase, and others
• Exocrine Pancreatic Insufficiency Therapeutic Assessment: Exocrine Pancreatic Insufficiency current marketed and Exocrine Pancreatic Insufficiency emerging therapies
• Exocrine Pancreatic Insufficiency Market Dynamics: Exocrine Pancreatic Insufficiency market drivers and Exocrine Pancreatic Insufficiency market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Exocrine Pancreatic Insufficiency Unmet Needs, KOL’s views, Analyst’s views, Exocrine Pancreatic Insufficiency Market Access and Reimbursement 

To know more about Exocrine Pancreatic Insufficiency companies working in the treatment market, visit @ Exocrine Pancreatic Insufficiency Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Exocrine Pancreatic Insufficiency Market Report Introduction

2. Executive Summary for Exocrine Pancreatic Insufficiency

3. SWOT analysis of Exocrine Pancreatic Insufficiency

4. Exocrine Pancreatic Insufficiency Patient Share (%) Overview at a Glance

5. Exocrine Pancreatic Insufficiency Market Overview at a Glance

6. Exocrine Pancreatic Insufficiency Disease Background and Overview

7. Exocrine Pancreatic Insufficiency Epidemiology and Patient Population

8. Country-Specific Patient Population of Exocrine Pancreatic Insufficiency 

9. Exocrine Pancreatic Insufficiency Current Treatment and Medical Practices

10. Exocrine Pancreatic Insufficiency Unmet Needs

11. Exocrine Pancreatic Insufficiency Emerging Therapies

12. Exocrine Pancreatic Insufficiency Market Outlook

13. Country-Wise Exocrine Pancreatic Insufficiency Market Analysis (2019–2032)

14. Exocrine Pancreatic Insufficiency Market Access and Reimbursement of Therapies

15. Exocrine Pancreatic Insufficiency Market Drivers

16. Exocrine Pancreatic Insufficiency Market Barriers

17.  Exocrine Pancreatic Insufficiency Appendix

18. Exocrine Pancreatic Insufficiency Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services